The compounding industry is trying to quell misconceptions about its GLP-1 products, which prescribers can order while branded versions of the drugs are in short supply.
The US Preventive Services Task Force issued a draft recommendation statement outlining the interventions that should be taken when a child or teen has a high body mass index.
The SELECT trial catapulted GLP-1 RAs into the forefront of CVD prevention, but cardiologists are making their own decisions about whether and how they might integrate these agents into practice.